TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · IEX Real-Time Price · USD
9.90
+0.28 (2.91%)
May 7, 2024, 1:14 PM EDT - Market open
TriSalus Life Sciences Revenue
In the year 2023, TriSalus Life Sciences had annual revenue of $18.51M with 49.31% growth. Revenue in the quarter ending December 31, 2023 was $5.72M with 77.34% year-over-year growth.
Revenue (ttm)
$18.51M
Revenue Growth
+49.31%
P/S Ratio
15.87
Revenue / Employee
$165,277
Employees
112
Market Cap
298.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18.51M | 6.11M | 49.31% |
Dec 31, 2022 | 12.40M | 4.00M | 47.58% |
Dec 31, 2021 | 8.40M | - | - |
Dec 31, 2020 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTLSI News
- 6 hours ago - TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors - Business Wire
- 20 hours ago - TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call - Business Wire
- 6 days ago - TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives - Business Wire
- 5 weeks ago - TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update - Business Wire
- 6 weeks ago - TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting - Business Wire
- 6 weeks ago - TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting - Business Wire
- 2 months ago - TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results - Business Wire
- 2 months ago - TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101 - Business Wire